Rep. Bruce Westerman Buys Edwards Lifesciences Co. (NYSE:EW) Stock

Representative Bruce Westerman (R-Arkansas) recently bought shares of Edwards Lifesciences Co. NYSE: EW. In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Edwards Lifesciences stock on March 3rd. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of LVMH Moët Hennessy - Louis Vuitton, Société Européenne OTCMKTS: LVMUY on 4/2/2025.
• Purchased $1,001 - $15,000 in shares of Sony Group NYSE: SONY on 3/24/2025.
• Purchased $1,001 - $15,000 in shares of Mitsubishi UFJ Financial Group NYSE: MUFG on 3/21/2025.
• Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 3/21/2025.
• Sold $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Medtronic NYSE: MDT on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 3/20/2025.

Edwards Lifesciences Stock Performance

EW traded down $2.30 on Monday, reaching $69.23. 3,767,362 shares of the stock were exchanged, compared to its average volume of 4,926,556. The company's 50-day moving average price is $71.31 and its 200 day moving average price is $70.92. The firm has a market capitalization of $40.70 billion, a PE ratio of 9.93, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,500 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the transaction, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,555,402. This represents a 12.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,853 shares of company stock worth $5,163,062 over the last three months. 1.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on EW. Barclays upped their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Finally, Truist Financial decreased their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $78.55.

Institutional Trading of Edwards Lifesciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Norges Bank acquired a new stake in Edwards Lifesciences during the fourth quarter worth $610,895,000. Jennison Associates LLC acquired a new position in Edwards Lifesciences in the fourth quarter worth about $555,939,000. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock worth $314,182,000 after buying an additional 3,506,886 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $213,844,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.